Article Text

Download PDFPDF
Clopidogrel and calcium-channel blockers: a clinically important interaction?

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding We are grateful for support from the NIHR Biomedical Research Centre funding scheme.

  • Competing interests NC has received honoraria from Pfizer, manufacturer of the calcium-channel blocker, amlodipine.

  • Provenance and peer review Commissioned; not externally peer reviewed.

Linked Articles